RxDoctor Payments Data

Brian Murphy, MD

Hematology & Oncology · Sandusky, OHNPI 1104877125

Payments from drug & device makers

$3,469in general payments, 2019–2025

Across 43 payments — averaging $80.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rigel Pharmaceuticals, Inc.$1K
  • Merck$995
  • Beigene USA, Inc.$277
  • E.r. Squibb & Sons, L.L.C.$270
  • Takeda Pharmaceuticals U.S.A., Inc.$108
  • Regeneron Healthcare Solutions, Inc.$103
  • plus $516 from 12 others

What the payments were for

  • Speaking & faculty fees$1,20047%
  • Food & beverage$99839%
  • Education$33113%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,469 in reported general payments places this provider in the 40th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$5,884,236
Medicare patients
619
Services billed
210,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib106$1,633,158
BrukinsaZanubrutinib96$1,371,754
RevlimidLenalidomide35$581,555
JaypircaPirtobrutinib20$449,816
XtandiEnzalutamide32$431,932
CabometyxCabozantinib S-Malate15$368,397
PomalystPomalidomide15$340,198
CalquenceAcalabrutinib Maleate33$321,113
Lenalidomide23$318,682
PromactaEltrombopag Olamine17$318,299
JakafiRuxolitinib Phosphate14$238,734
Abiraterone Acetate99$224,534
ImbruvicaIbrutinib13$213,145
MekinistTrametinib Dimethyl Sulfoxide12$184,487
TafinlarDabrafenib Mesylate12$169,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$35$1,681,509172 claims
Beigene USA, Inc.Brukinsa$277$1,371,75496 claims
NovartisPromacta, Mekinist, Tafinlar$24$672,70841 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$270$340,19815 claims
AstraZenecaCalquence$95$321,11333 claims
Incyte CorporationJakafi$77$238,73414 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$108$161,92213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →